noom glp-1 introduces longevity-focused microdosing with at-home biomarker tracking Why We Launched Noom GLP-1RX

lilly.com This article reports the weight loss efficacy of the unimolecular GLP1RGIPRGCGR tri-agonist retatrutide in people with obesity and osteoarthritis

28 Ninety patients were included in the trial, randomized to receive ALC 1,000 mg/day (500 mg intramuscularly twice daily) during the 14-day double-blind phase

The US Food and Drug Administration (FDA) has approved oral and intravenous (IV) L-carnitine for the treatment of primary and secondary carnitine deficiency as a result of inborn errors of metabolism

Up-modulation of PLC-2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133+/EpCAM+ phenotype: a promising target for preventing progression of TNBC